Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1950 2
1951 1
1952 1
1954 2
1956 8
1957 1
1958 1
1959 1
1961 1
1962 1
1963 1
1964 5
1965 5
1966 2
1968 3
1969 4
1970 3
1971 4
1972 3
1973 3
1974 2
1975 1
1976 1
1977 1
1978 3
1980 2
1981 3
1982 1
1983 1
1984 3
1985 1
1986 2
1987 1
1988 6
1990 2
1991 4
1992 1
1993 4
1994 7
1995 1
1996 4
1997 12
1998 5
1999 6
2000 8
2001 5
2002 12
2003 5
2004 13
2005 7
2006 10
2007 15
2008 24
2009 24
2010 28
2011 25
2012 40
2013 42
2014 44
2015 47
2016 35
2017 42
2018 32
2019 36
2020 44
2021 56
2022 51
2023 52
2024 54

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

797 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Among authors: figueroa ms. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Nutritional Considerations for the Neonate With Congenital Heart Disease.
Mills KI, Kim JH, Fogg K, Goldshtrom N, Graham EM, Kataria-Hale J, Osborne SW, Figueroa M. Mills KI, et al. Among authors: figueroa m. Pediatrics. 2022 Nov 1;150(Suppl 2):e2022056415G. doi: 10.1542/peds.2022-056415G. Pediatrics. 2022. PMID: 36317972 Review.
Optical coherence tomography-based consensus definition for lamellar macular hole.
Hubschman JP, Govetto A, Spaide RF, Schumann R, Steel D, Figueroa MS, Sebag J, Gaudric A, Staurenghi G, Haritoglou C, Kadonosono K, Thompson JT, Chang S, Bottoni F, Tadayoni R. Hubschman JP, et al. Among authors: figueroa ms. Br J Ophthalmol. 2020 Dec;104(12):1741-1747. doi: 10.1136/bjophthalmol-2019-315432. Epub 2020 Feb 27. Br J Ophthalmol. 2020. PMID: 32107208 Review.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Stahl M, et al. Among authors: figueroa me. Blood Rev. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. Blood Rev. 2023. PMID: 37704469 Review.
Reply.
Govetto A, Lalane RA 3rd, Sarraf D, Hubschman JP, Figueroa MS. Govetto A, et al. Among authors: figueroa ms. Am J Ophthalmol. 2017 May;177:227-229. doi: 10.1016/j.ajo.2017.02.005. Epub 2017 Mar 3. Am J Ophthalmol. 2017. PMID: 28262181 No abstract available.
Reply.
Figueroa MS, Govetto A, Contreras I, Ruiz-Moreno JM, del Valle FG, Plascencia RN, Medina JL. Figueroa MS, et al. Retina. 2016 Jan;36(1):e4-5. doi: 10.1097/IAE.0000000000000915. Retina. 2016. PMID: 26702607 No abstract available.
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. Lu C, et al. Among authors: figueroa me. Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860. Nature. 2012. PMID: 22343901 Free PMC article.
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Figueroa ME, et al. Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9. Cancer Cell. 2010. PMID: 21130701 Free PMC article.
797 results